Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.
OBJECTIVE
We investigated the relationship between the tertiary Gleason component in radical prostatectomy specimens and biochemical recurrence in what is to our knowledge the largest single institution cohort to date.


METHODS
We evaluated data on 3,230 men who underwent radical prostatectomy at our institution from 2000 to 2005. Tertiary Gleason component was defined as Gleason grade pattern 4 or greater for Gleason score 6 and Gleason grade pattern 5 for Gleason score 7 or 8.


RESULTS
Biochemical recurrence curves for cancer with tertiary Gleason component were intermediate between those of cancer without a tertiary Gleason component in the same Gleason score category and cancer in the next higher Gleason score category. The only exception was that Gleason score 4 + 3 = 7 with a tertiary Gleason component behaved like Gleason score 8. The tertiary Gleason component independently predicted recurrence when factoring in radical prostatectomy Gleason score, radical prostatectomy stage and prostate specific antigen (HR 1.45, p = 0.029). Furthermore, the magnitude of the tertiary Gleason component effect on recurrence did not differ by Gleason score category (p = 0.593).


CONCLUSIONS
Although the tertiary Gleason component is frequently included in pathology reports, it is routinely omitted in other situations, such as predictive nomograms, research studies and patient counseling. The current study adds to a growing body of evidence highlighting the importance of the tertiary Gleason component in radical prostatectomy specimens. Accordingly consideration should be given to a modified radical prostatectomy Gleason scoring system that incorporates tertiary Gleason component in intuitive fashion, including Gleason score 6, 6.5 (Gleason score 6 with tertiary Gleason component), 7 (Gleason score 3 + 4 = 7), 7.25 (Gleason score 3 + 4 = 7 with tertiary Gleason component), 7.5 (Gleason score 4 + 3), 8 (Gleason score 4 + 3 with tertiary Gleason component or Gleason score 8), 8.5 (Gleason score 8 with tertiary Gleason component), 9 (Gleason score 4 + 5 or 5 + 4) and 10.
Trock
Bruce J
BJ
Department of Urology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA.
Guo
Charles C
CC
Gonzalgo
Mark L
ML
Magheli
Ahmed
A
Loeb
Stacy
S
Epstein
Jonathan I
JI
D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery*; D012189:Retrospective Studies
D017430:Prostate-Specific Antigen
Am J Surg Pathol. 2004 Mar;28(3):394-8
15104304
Lancet Oncol. 2007 May;8(5):411-9
17466898
J Urol. 2008 Feb;179(2):516-22; discussion 522
18076949
Cancer. 2003 Dec 15;98(12):2560-5
14669274
Am J Surg Pathol. 2000 Apr;24(4):563-9
10757404
J Urol. 2008 May;179(5):1775-9
18343432
J Urol. 1974 Jan;111(1):58-64
4813554
JAMA. 1999 Apr 21;281(15):1395-400
10217055
JAMA. 2007 Oct 3;298(13):1533-8
17911498
Urology. 2000 Nov 1;56(5):823-7
11068310
J Urol. 1967 Feb;97(2):331-7
6018430
J Urol. 2006 May;175(5):1695-9; discussion 1699
16600733
Am J Surg Pathol. 2005 Sep;29(9):1228-42
16096414
Eur Urol. 2005 Oct;48(4):572-6
16046051